Phase II trial

Diabetic macular oedema
#Biopharmaceuticals #Diabetes #Ophthalmology #Phase II trial #Rezolute

Oral therapy for diabetic macular oedema progresses to Phase II

Biopharmaceutical company Rezolute has initiated a Phase II proof-of-concept study for RZ402, a plasma kallikrein inhibitor (PKI) being developed as an oral therapy for the treatment of diabetic macular oedema (DMO).   The current standard of care for DMO is anti-vascular growth factor (anti-VEGF) injections into the eye,… Read More

#News

Heart attack patient with doctor
#Heart attack #Monoclonal antibodies #Phase II trial

UK trial will test new mAb treatment in heart attack patients

A potential new drug to improve the long-term outcomes for heart attack patients will be trialled in the UK under a new agreement.  The Phase IIb LIBERATE study will test the tolerance and the efficacy of glenzocimab 1000mg to reduce heart damage following a myocardial infarction (MI). Read More

#News

Patient taking antibiotics
#Antibiotics #GSK #Phase II trial #TB #Tuberculosis

New class of antibiotics could help address the TB epidemic 

A first-in-class investigational antitubercular agent has shown early bactericidal activity with a low, once-daily oral dose after 14 days of treatment.  The Phase IIa study evaluated GSK’s GSK3036656 in participants with drug-susceptible pulmonary tuberculosis. The company hopes GSK3036656 could be a component of simpler treatment regimens in… Read More

#News #Trending News

Arsenic Trioxide
#Anti-inflammatory #Arsenic Trioxide #Autoimmune disease #Graft vs Host Disease #Phase II trial #Stem cell transplant #Transplant

Phase II success for autoimmune disease platform in GVHD

BioSenic’s arsenic trioxide (ATO) autoimmune disease platform has completed a successful Phase IIb trial in chronic Graft vs Host Disease (cGVHD) and is preparing to move to a Phase III trial.  The BioSenic autoimmune platform was created by Medsenic to target systemic autoimmune diseases using ATO as… Read More

#News

Mosquito against yellow background
#Malaria #Monoclonal antibodies #National Institute of Allergy and Infectious Diseases #Phase II trial #Sub-Saharan Africa

Monoclonal antibody could transform malaria prevention

One dose of an antibody drug safely protected healthy, non-pregnant adults from malaria infection during an intense six-month malaria season in Mali, Africa.   The antibody was up to 88.2% effective at preventing infection over a 24-week period, demonstrating for the first time that a monoclonal antibody can… Read More

#News #Trending News